Consequently, abatacept (no effects on MS), IFNB (no effects on RA), azathioprine (insufficient effects on MS), and BTK inhibitors (no effects on RA) are unlikely to provide a meaningful treatment response in people with MS and comorbid RA [23–28, 34–43, 75]. Here, IFNB1 is linked to myeloid sarcoma.